Health
Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch
Johnson & Johnson
JNJ,
-1.69%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine provided a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates, the company said. Based on the strength of the data, a Phase 1/2a first-i…
-
Business21 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News7 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General21 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts